medicina58巻1号

2021年01月発行

特集 エキスパートに学ぶ—最新の循環器治療薬の使い方 知っておくべき10種類の循環器治療薬と治療法

—心不全に対する新規治療薬・3—sGC刺激薬：アデムパス^®，vericiguat

著者： 杦山陽一¹ 田原宣広¹ 福本義弘¹

所属機関： ¹久留米大学医学部内科学講座心臓・血管内科部門

ページ範囲：P.32 - P.37

Question 1
可溶性グアニル酸シクラーゼ（sGC）刺激薬ってどのような薬ですか？

参考文献

1）Ghofrani HA, et al：Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369：330-340, 2013

2）Ghofrani HA, et al：Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension；Data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 4：361-371, 2016

3）Ghofrani HA, et al：Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369：319-329, 2013

4）Humbert M, et al：Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 130：2189-2208, 2014

5）Humbert M, et al：Treatment of pulmonary arterial hypertension. N Engl J Med 351：1425-1436, 2004

6）Hoeper MM, et al：RESPITE；Switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 50：1602425, 2017

7）Califf RM, et al：A randomized controlled trial of epoprostenol therapy for severe congestive heart failure；The Flolan International Randomized Survival Trial（FIRST）. Am Heart J 134：44-54, 1997

8）Mylona P, Cleland JG：Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1：197-200, 1999

9）Vachiéry JL, et al：Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 51：1701886, 2018

10）Guazzi M, et al：Pulmonary hypertension in heart failure with preserved ejection fraction；A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124：164-174, 2011

11）Redfield MM, et al：Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction；A randomized clinical trial. JAMA 309：1268-1277, 2013

12）Ghio S, et al：Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial（LEPHT）；Rationale and design. Eur J Heart Fail 14：946-953, 2012

13）Bonderman D, et al：Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure（DILATE-1）；A randomized, double-blind, placebo-controlled, single-dose study. Chest 146：1274-1285, 2014

14）Galiè N, et al：The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension；A practical chronicle of progress. Eur Respir J 46：903-975, 2015

15）Fukuda K, et al：Guidelines for the treatment of pulmonary hypertension（JCS 2017/JPCPHS 2017）. Circ J 83：842-945, 2019

16）Armstrong PW, et al：Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382：1883-1893, 2020

17）Bocchi EA, et al：Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol 74：70-72, 1994